贝利尤单抗与抗疟药联合预防接受肾外系统性红斑狼疮治疗患者的肾脏复发:四项III期临床试验结果
该研究汇总BLISS-52、BLISS-76、BLISS-SC和BLISS-Northeast Asia四项III期试验共3225例活动性SLE但无严重活动性肾炎患者的数据,评估抗疟药及不同剂量和剂型贝利尤单抗对肾脏复发的预防作用。结果显示,静脉贝利尤单抗10 mg/kg和1 mg/kg及抗疟药使用均与肾脏复发风险降低相关,贝利尤单抗与抗疟药联合时保护作用增强,皮下贝利尤单抗200 mg未见显著关联。
要点
- 静脉贝利尤单抗10 mg/kg(HR 0.62)和1 mg/kg(HR 0.42)较安慰剂降低肾脏复发风险。
- 抗疟药使用与肾脏复发风险降低相关(HR 0.66,95%CI 0.55,0.78,P<0.001)。
- 贝利尤单抗与抗疟药联合时保护作用增强,静脉贝利尤单抗1 mg/kg联合抗疟药复发率最低(18.5例/1000人年)。
核心结论
- 在因肾外SLE接受治疗的患者中,贝利尤单抗对肾脏复发发展的保护作用在与抗疟药联合给药时似乎增强。
- 低剂量贝利尤单抗的突出效应值得研究中间剂量贝利尤单抗的疗效。
研究设计与样本
- 汇总BLISS-52、BLISS-76、BLISS-SC和BLISS-Northeast Asia四项贝利尤单抗III期试验的数据,共纳入3225例活动性SLE但无严重活动性肾炎的患者。
- 参与者被分配接受静脉贝利尤单抗1 mg/kg、静脉贝利尤单抗10 mg/kg、皮下贝利尤单抗200 mg或安慰剂,均加标准治疗。
- 使用Cox回归分析估计整个研究随访期间(52-76周)发生肾脏复发的风险。
主要发现
- 共192例患者发生肾脏复发,中位时间为197天。
- 与安慰剂相比,接受静脉贝利尤单抗10 mg/kg的患者肾脏复发风险较低(HR 0.62,95%CI 0.41,0.92,P=0.018)。
- 与安慰剂相比,接受静脉贝利尤单抗1 mg/kg的患者肾脏复发风险较低(HR 0.42,95%CI 0.22,0.79,P=0.007)。
- 皮下贝利尤单抗200 mg与肾脏复发风险无显著关联。
- 抗疟药使用与较低的肾脏复发风险相关(HR 0.66,95%CI 0.55,0.78,P<0.001)。
关键数值与推荐
- 静脉贝利尤单抗10 mg/kg较安慰剂的肾脏复发HR为0.62(95%CI 0.41,0.92,P=0.018)。
- 静脉贝利尤单抗1 mg/kg较安慰剂的肾脏复发HR为0.42(95%CI 0.22,0.79,P=0.007)。
- 抗疟药使用的肾脏复发HR为0.66(95%CI 0.55,0.78,P<0.001)。
- 静脉贝利尤单抗1 mg/kg联合抗疟药的肾脏复发率为18.5例/1000人年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the effect of antimalarial agents (AMA) and different doses and pharmaceutical forms of belimumab on preventing renal flares in patients with SLE treated for extra-renal disease. METHODS: We pooled data from the BLISS-52, BLISS-76, BLISS-SC and BLISS-Northeast Asia trials of belimumab (n = 3225), that included patients with active SLE yet no severe ongoing nephritis. Participants were allocated to receive intravenous belimumab 1 mg/kg, intravenous belimumab 10 mg/kg, subcutaneous belimumab 200 mg, or placebo in addition to standard therapy. We estimated hazards of renal flare development throughout the study follow-up (52-76 weeks) using Cox regression analysis. RESULTS: In total, 192 patients developed a renal flare after a median of 197 days. Compared with placebo, the risk of renal flares was lower among patients receiving intravenous belimumab 10 mg/kg (HR: 0.62; 95% CI: 0.41, 0.92; P = 0.018) and intravenous belimumab 1 mg/kg (HR: 0.42; 95% CI: 0.22, 0.79; P = 0.007), while no significant association was found for subcutaneous belimumab 200 mg. AMA use yielded a lower hazard of renal flares (HR: 0.66; 95% CI: 0.55, 0.78; P < 0.001). The protection conferred was enhanced when belimumab and AMA were co-administered; the lowest flare rate was observed for the combination intravenous belimumab 1 mg/kg and AMA (18.5 cases per 1000 person-years). CONCLUSIONS: The protection conferred from belimumab against renal flare development in patients treated for extra-renal SLE appears enhanced when belimumab was administered along with AMA. The prominent effect of low-dose belimumab warrants investigation of the efficacy of intermediate belimumab doses. CLINICAL TRIAL IDENTIFICATION: BLISS-52: NCT00424476; BLISS-76: NCT00410384; BLISS-SC: NCT01484496; BLISS-NEA: NCT01345253.
引用
- Gomez A, Jägerback S, Sjöwall C, et al. Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials. Rheumatology (Oxford). 2024. PMID: 37228028. doi:10.1093/rheumatology/kead253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。